Option chain shows key data for LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC.

LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC (OTC:LNDNS) Stock, Option Chain

LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and raises the price target from $9 to $11.

News

Price Target

Analyst Ratings

PSNL

HC Wainwright & Co. Maintains Buy on Personalis, Raises Price Target to $11

Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024 GAAP And Non-GAAP Results

Raymond James analyst Steve Moss upgrades Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) from Market Perform to Outperform and announces $50 price target.

Upgrades

Raymond James Upgrades Camden National to Outperform, Announces $50 Price Target

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and raises the price target from $12 to $15.

Reiteration

HUMA

HC Wainwright & Co. Reiterates Buy on Humacyte, Raises Price Target to $15

Chardan Capital analyst Rudy Li initiates coverage on Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy rating and announces Price Target of $24.

Initiation

STOK

Chardan Capital Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $24

Trump Media &amp; Technology Group Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) experienced a notable decline in its stock value. The company&#8217;s shares fell by 5.31% during pre-market trading on Friday, coinciding with a major decision by&nbsp;Donald Trump.
What Happened: Trump Media &amp; Technology Group Corp saw its shares fall by 5.31% <a href="https://www.benzinga.com/markets/equities/24/12/42609228/trump-transfers-entire-djt-stake-to-revocable-trust-ahead-of-inauguration">during pre-market trading</a> on Friday. according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This decline follows Donald Trump&#8216;s decision to transfer his entire stake in the company to his revocable trust.
The transfer involved 114,750,000 shares, which equates to about 53% of the company&#8217;s ownership. The transaction was completed on Tuesday, with Trump named as the sole beneficiary, as per&nbsp;Securities and Exchange Commission filings&nbsp;released on Thursday.
The shares were transferred to the&nbsp;Donald J. Trump Revocable Trust&nbsp;without any monetary exchange. This move comes shortly after Trump participated in ringing&nbsp;the opening bell at the&nbsp;New York Stock Exchange, where&nbsp;DJT&#8217;s stock has more than doubled in value this year.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/12/42567762/bitcoin-ethereum-dogecoin-fall-after-fed-shows-no-interest-for-piling-btc-top-analyst-says-sentiment-shifting-2025-suddenly-looks-a-lot-less-rosy?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Fall After Fed Shows No Interest For Piling BTC: Top Analyst Says Sentiment Shifting — &#8216;2025 Suddenly Looks A Lot Less Rosy&#8217;</a>
On Tuesday, the company&#8217;s shares closed at $35.41, putting the value of Trump&#8217;s transferred stake at roughly $4 billion. This transfer follows Trump&#8217;s earlier promise in September&nbsp;not to sell his shares&nbsp;in the Truth Social parent&nbsp;company. At that time, he had criticized Nasdaq for routine trading halts and suggested a possible move to the NYSE.
Why It Matters: The transfer of&nbsp;Trump&#8217;s&nbsp;stake in&nbsp;Trump Media &amp; Technology Group Corp&nbsp;comes at a time when the company has seen significant growth. Earlier this year, DJT&#8217;s stock value had more than doubled, reflecting investor confidence in the company&#8217;s potential. However, Trump&#8217;s decision to transfer his shares to a revocable trust raises questions about his future involvement in the company.
In September, Trump had publicly criticized Nasdaq for its trading halts, hinting at a potential shift to the New York Stock Exchange. This move was seen as a strategic effort to align with a more stable trading environment. The recent transfer of shares to the trust could be part of a broader strategy to manage his assets while maintaining influence over the company.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42550405/trump-inauguration-could-coincide-with-a-harrowing-dump-for-crypto-arthur-hayes-warns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Inauguration Could Coincide With A &#8216;Harrowing Dump&#8217; For Crypto, Arthur Hayes Warns</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Flickr

Equities

Pre-Market Outlook

Markets

General

DJT Stock Plummets Over 5% Following Trump's Stake Transfer: Here's More

Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">lower in the premarket session on Friday.</a>
The company revealed it had successfully closed a transaction with accredited and institutional investors, issuing units consisting of shares of Class A common stock (or Pre-funded Warrants in lieu) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42603702/sidus-space-announces-closing-of-14-million-private-placement" rel="noreferrer noopener">along with Common Warrants.</a>
The offering raised approximately $14.1 million in gross proceeds, before deducting fees and expenses.
The company issued 6.82 million shares of Class A common stock (or Pre-funded Warrants) and accompanying Common Warrants, allowing investors to purchase an additional 3.41 million shares at an exercise price of $2.25 per share over the next five and a half years. Each Pre-funded Warrant has an exercise price of $0.0001 per share.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42611748/us-stocks-to-open-lower-as-traders-brace-for-triple-witching-hour-analyst-says-end-of-the-year-recovery-would-not-surprise-anyone" rel="noreferrer noopener">US Stocks To Open Lower As Traders Brace For &#8216;Triple Witching&#8217; Hour: Analyst Says End Of The Year Recovery &#8216;Would Not Surprise Anyone&#8217;</a>
Sidus plans to use the proceeds from this offering for working capital and general corporate purposes. ThinkEquity served as the exclusive placement agent for the transaction.
In November, Sidus Space provided an update <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42188959/sidus-space-announces-lizziesat-2-ready-for-launch" rel="noreferrer noopener">on the progress of its LizzieSat-2 satellite.</a>
The satellite has completed launch processing at the Astrotech Space Operations facility at Vandenberg Space Force Base, California, and has been handed over to SpaceX for the upcoming Bandwagon-2 rideshare mission, scheduled for December 2024.
LizzieSat-2, developed at Sidus Space&#8217;s Florida facility, features advanced sensors such as AIS, multi-spectral methane detection, and high-resolution visual spectrum sensors, alongside the HEO Holmes Imager, developed by HEO (USA), a subsidiary of Australia-based HEO.
Price Action: SIDU shares are trading lower by 7.10% to $4.58 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why" target="_blank" rel="noreferrer noopener">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here's Why</a></li>
</ul>

Offerings

Movers

SIDU

Sidus Space Closes $14.1 Million Capital Raise: Details

HC Wainwright &amp; Co. analyst Andrew Fein initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy rating and announces Price Target of $72.

HC Wainwright & Co. Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $72

The collaboration aims to evaluate Eye-Net's cutting-edge cellular vehicle-to-everything (C-V2X) technology as a key component in advanced driver assistance systems, potentially setting a new standard for road safety.

FRSX

Foresight Autonomous Says That Its Wholly Owned Subsidiary Eye-net Mobile Inked Multi-phase Agreement With Softbank Corp. And A Leading Japanese Vehicle Manufacturer

Evercore ISI Group analyst Josh Schimmer downgrades Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) from Outperform to In-Line and maintains the price target from $5 to $5.

Downgrades

SPRO

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $75 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $75 Price Target

Following a sluggish session on Thursday and a fall on Wednesday after the Fed&#8217;s <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">hawkish</a> rate cut, Wall Street is now bracing for Friday&#8217;s &#8220;Triple Witching&#8221; session which is slated to see about $6.6 trillion options to expire.
What Happened: The &#8220;Triple Witching&#8221; hour is a quarterly event that occurs during the final hour of trade on the third Friday of March, June, September, and December. During this period, contracts for stock index futures, stock index options, and stock options all expire at the same time.
According to the Singapore-based broker, uSMART, Friday, Dec. 20 marks the notorious &#8216;Triple Witching&#8217; day, when the total options contracts worth $5.2 trillion on the S&amp;P 500 index, $710 billion worth of contracts on single stocks and $735 billion worth of contracts on the Nasdaq 100, Russell 200 and others are set to expire.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f4a1;This Friday&#39;s &quot;Triple Witching Day&quot; is expected to be the largest options expiration day in history, with a total of over $6 trillion in options tied to stocks, exchange-traded funds (ETFs), and indices set to expire. <a href="https://twitter.com/hashtag/stocks?src=hash&amp;ref_src=twsrc%5Etfw">#stocks</a> <a href="https://twitter.com/hashtag/ETFs?src=hash&amp;ref_src=twsrc%5Etfw">#ETFs</a> <a href="https://t.co/ExaqHgfzX5">pic.twitter.com/ExaqHgfzX5</a>
&mdash; uSMART (@usmartsg) <a href="https://twitter.com/usmartsg/status/1870010390471684367?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The total $6.6 trillion worth of option contracts can be further divided into four categories. Here&#8217;s what they include:
<ul>
<li>About $4.5 trillion notional worth of index options contracts.</li>
<li>$685 billion notional worth of options on futures.</li>
<li>$745 billion notional worth of options on exchange-traded funds.</li>
<li>$710 billion notional worth of contracts on single stocks.</li>
</ul>
&#8220;The timing of buying the dip is complicated by options expiration tomorrow and Christmas next week, but a recovery by the end of the year would not surprise anyone,&#8221; said Louis Navellier, founder of Navellier &amp; Associates.
See Also: <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">Nike&#8217;s New CEO Blames Promotions For Declining Profits, Says Turnaround Efforts May Hurt As Company Moves To Clear Excess Inventory</a>
Why It Matters: This &#8220;Triple Witching&#8221; convergence can lead to heightened market volatility as traders close, roll over, or offset their expiring contracts, often resulting in unusual price movements and increased trading volumes.
Looking back at the last few triple-witching events, the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has struggled during these high-stakes trading days.
<ul>
<li>Sept. 20, 2024: Decline of 0.2%.</li>
<li>Jun. 21, 2024: Decline of 0.5%.</li>
<li>Mar. 15, 2024: Decline of 1%.</li>
<li>Dec. 15, 2023: Decline of 0.6%.</li>
</ul>
Tech stocks, represented by the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), fell in the last three triple-witching occasions, dropping 0.19% in September, 0.8% in June and 1.2% in March, while surging 0.5% in December 2023.
Price Action: U.S. stock futures declined, ahead of the &#8216;Triple Witching&#8217; Friday. All four major indices were trading lower.
In premarket trading, the SPDR S&amp;P 500 ETF Trust was down 1.05% to $579.97 and the Invesco QQQ Trust ETF fell 1.26% to $507.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.75%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.24%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Shutterstock

Futures

Options

The $6.6 Trillion Question: Can Markets Weather Triple Witching And Hawkish Fed Signals? Here's What This Analyst Says

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Outperform to In-Line and lowers the price target from $15 to $6.

CABA

Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6

Novo Nordisk Spokesperson Said Regulatory Submission Of Cagrisema Is Expected Towards The End Of 2025

Novo Nordisk Spokesperson Said Cagrisema Trial Permitted Dose Reductions; Statistically Significant Results Were Achieved Even Though Only 57% Of Patients On Cagrisema Reached The Highest Dose

Oppenheimer analyst Leland Gershell initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform rating and announces Price Target of $76.

RYTM

Oppenheimer Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating, Announces Price Target of $76

Cable One currently owns a 45% stake in MBI, and affiliates of GTCR LLC ("GTCR") and MBI management own the balance of MBI. The amendments provide Cable One with enhanced ability to control the timing for acquiring the 55% interest it does not currently own pursuant to the put right held by GTCR, with any such acquisition to occur no earlier than October 1, 2026 unless Cable One elects to close the transaction at an earlier date.

CABO

Cable One Announced That It Has Amended The Terms Of Its Strategic Investment In Mega Broadband Investments Holdings To Provide Enhanced Timing Flexibility For Cable One's Potential Acquisition Of Full Ownership Of MBI

Canaccord Genuity analyst Joseph Vafi maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and maintains $5.75 price target.

BLND

Canaccord Genuity Maintains Buy on Blend Labs, Maintains $5.75 Price Target

RSLS

Reshape Lifesciences Inc Files For Offering Of Up To 2.1M Shares Of Common Stock By Selling Stockholder

BiXin is a manufacturer of chillers, heat pumps, heat-recovery solutions and air-handling units. Focused on expanding the Vertiv chiller family, the acquisition strengthens Vertiv's portfolio of critical technologies and solutions in support of high-performance compute and AI applications globally.

Comments

LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC

LANDA APP 2 3195 LK MNRO by LANDA APP 2 LLC (LNDNS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga